• Proprietary Polyamide Balloon with 3 folds for optimal trackability across long lesions in BTK area
• Paclitaxel Drug - 3.0μg/mm2 (highly lipophilic drug) (Gold Standard in DCB)
• BTHC Coating (Bio-compatible and safe FDA /CE Approved) effective for prevention of “Wash Away Effect” - the excipient also assists to the Drug uptake
![](/uploads/s/q/i/m/qimvmp501gj4/img/full_zLEFt8yX.png)
![](/uploads/s/q/i/m/qimvmp501gj4/img/full_wtDg07T7.png)
![](/uploads/s/q/i/m/qimvmp501gj4/img/full_k0S4QBLF.png)
![](/uploads/s/q/i/m/qimvmp501gj4/img/full_P55yMFxw.png)
In peripheral artery disease, DCB therapy has proven superior to balloon angioplasty for treatment of de novo femoropopliteal and below-the-knee disease.
The Excipient
The excipient is a crucial part of a drug-eluting balloon, as it may have a direct effect on the drug uptake. The rationale behind a higher drug uptake lies in the effect of the excipient.
Another benefit of excipients may be the smooth dispersion of the drug in the excipient matrix increasing the uptake
![](/uploads/s/q/i/m/qimvmp501gj4/img/full_G1dLBOFK.png)
![](/uploads/s/q/i/m/qimvmp501gj4/img/full_0mQuZS04.png)
![](/uploads/s/q/i/m/qimvmp501gj4/img/full_E8CQiNEl.png)
Paclitaxel Eluting Peripheral Balloon Dilatation Catheter
![](/uploads/s/q/i/m/qimvmp501gj4/img/full_fUwBkgYS.png)
![](/uploads/s/q/i/m/qimvmp501gj4/img/full_W9qQUgNA.png)